Investor Presentaiton
Wuxi ATU is Well Positioned to Transform CGT Industry to Reach its Full
Potentials to Make CGT Products Affordable for Many Patients
01
Our integrated CTDMO model will drive strong growth in years to come and enable CGT industry
efficiently develop and commercialize game changing therapies for patients in need
WuXi
ATU
50
05
02
Our technology and manufacturing platforms will continuously improve
productivity and drive down manufacturing costs of CGT products
03
Our integrated testing, development and manufacturing platform enables us to
meet very tight Vein-to-Vein turnaround time requirements for cell therapies
04
H
TESSA and Stable Lenti-Cell Line technology will transform future AAV and LVV
manufacturing
Our track record and reputation of supporting customers to develop CGT products from DNA to
IND to BLA and commercialization will enable us to grow strongly in years to come
? Wuxi AppTec
药明康德View entire presentation